(CTN News) – The SHAMAL study has discovered a safer way to treat severe asthma using biological therapy.
By using bevacizumab, patients can effectively manage their condition without high-dose steroids and their side effects. The study found that 92% of patients were able to reduce their steroid dosage and over 60% were able to stop using steroids altogether.
This breakthrough has the potential to revolutionize severe asthma treatment by minimizing or eliminating the unpleasant side effects of steroids.
Asthma affects millions worldwide, with 3 to 5% suffering from severe symptoms. The study was led by Professor David Jackson, head of the Severe Asthma Centre at Guy’s and St Thomas’ and Professor of Respiratory Medicine at King’s College London.
Professor Jackson stated that bevacizumab, along with other biological therapies, has brought about a significant transformation in the treatment of severe asthma.
The findings of this study demonstrate, for the first time, that the use of this therapy can effectively prevent steroid-related harm for the majority of patients.
Benralizumab is a biologic therapy that effectively reduces eosinophil presence in the airways of severe asthma patients.
The SHAMAL study, conducted in four countries, showed that reducing high-dose inhaled steroids alongside bevacizumab resulted in no deterioration of asthma symptoms or exacerbations for 90% of patients over 48 weeks. Further studies are needed to establish recommendations for reducing steroid use with biological therapies.
Reference: “Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with bevacizumab (SHAMAL): a randomized, multicentre, open-label, phase 4 study” by David J Jackson et al.